Subject Index

A
Active hexose correlated compound (AHCC), 412
Activity management, 381–382
Acupuncture treatment, 385–386
for gastric cancer, 129–130
point injection, 179
vitamin K3 for, 178
prescription one
Qimen points, 179
Sanyinjiao points, 179
Yanglingquen points, 179
Zhangmen points, 179
Zusanli point, 179
prescription two
Ashi points, 179
Baihui points, 179
Ganyu points, 179
Mingmen points, 179
Neiguan points, 179
Sanyinjiao points, 179
Shenyu points, 179
YangLing points with
Chinese traditional medicines injections, 178
Zi wu liu zhu principle, 178
Acute lymphoblastic leukemia, 69
Acute myeloblastic leukemia, 52
Acute myeloid leukemia (AML), 67
Acute nephrotoxicity, 408
Acute pro-myelocytic leukemia (APML), 67
Adenosine triphosphate (ATP)
infusion, 374
Adjuvant Navelbine International Trialist Association (ANITA)
trials, 10, 12
Adriamycin, 52
Adverse drug reaction (ADR) reporting systems, 459
Agosterol A steroids structure, 623
Aitong powder, 177
Ajoene, 466
See also Garlic
Allicin, 466
See also Garlic
Allium sativum, see Garlic
American Joint Commission on Cancer
tumor/node/metastasis schema, 5
9-Aminocamptothecin, 404
AML, see Acute myeloid leukemia (AML)
Amrita, see Tinospora glabra
Anacarcin Forte, 53
Anacardiflavanone, 50
Anatomic segmentectomy, 8
See also Non-small cell lung cancer (NSCLC)
Androgen receptor (AR)
  abiraterone acetate and novel antiandrogens, 676
  antiandrogens, 677
AR LBD
  crystal structures of, 677
domains and, 676
C-terminal helix-12 (H12), 674
DBD, 673
HRPC, 677
and LBD, 673–674
mutations in AR genes, 676
NTD containing AF-1, 673
signaling, 673
studies, 674
Angelica dahurica extract
  for upper respiratory tract, 474
  for viral and bacterial infections, 474
Angong Huangti pills, 176
ANITA, see Adjuvant Navelbine International Trialist Association (ANITA)
Anti angiogenesis therapy, 15
agents, 7
Anticancer agents, 411
Antimetabolites, DNA poisons, 6
Anti-VEGF monoclonal antibody, 7
APML, see Acute pro-myelocytic leukemia (APML)
Ar-Curcumene, 58
Aroma therapy, 386
Ashwagandha, see Withania somnifera L.
Auricular acupuncture, 129
Avastin, see Bevacizumab
Ayurvedic medicine, 25, 405
art–science of health
  Charak Samhita, 35
  Sushrut Samhita, 35
  Vaata, Pitta and Kapha, 35
  Vedic, 35
camptothecin, 33
in cancer management, 34
case records, 63–65
energy level, 66–67
patient condition, 66
Centella asiatica, 34
Croscus sativus, 34
in de novo cases of acute premyelocytic leukemia, 68–69
diseases
  Agnikarma, 37
  Apachi, 36
  Apunarbhav chikitsa, 37
  Arbud, 36
dietary advice and avoidance, 37
  Galganda, 36
  Granthi, 36
  Gulma, 37
  Ksharkarma, 37
  lesions, 37
  marma, 37
  multiplicity or recurrence of tumors, 37
  shodhan and shaman, 37
  Vidradhi, 37
Eclipta alba, 34
etoposide, 33
Lippia nodiflora, 34
management, drugs used
  Basant Malti, 68
  Kamadudha, 68
  Navjeevan, 68
  Valipani, 68
medicinal plants/formulations for cancer therapy, 35
Papaverum somniferum, 34
physician, dilemma and approach, 38
podophyllotoxin, 33
Pongamia pinnata, 34
Poorva-Karma in cancer, 34
prescription for management of cancer, 34
principles of
  asthi and majja, 36
  Dhatus, 36
  mamsa and meda, 36
mind–body relationship, 36
rasa and rakta, 36
shukra, 36
scientific basis for, 33
Shorea robusta, 34
taxol, 33
vinca alkaloids, 33

B
Bai Zhi formulation, 219
Benign prostatic hyperplasia (BPH) treatment with
African potato, 470–471
Pygeum, 470–471
rye pollen, 470
Saw palmetto, 470
stinging nettle, 470–471
Bevacizumab for metastatic cancers, 7
Bhilwanol A, see Catechol I
Bhrigu-Samhita, 32
Bicalutamide, 676
Biflavanones, 50
Bingdong zhidi mixture, 175
Bing Pian, 214 formulation for pain, 199 liquor, 178
Bladder cancer (cont.)
uremia, 331–333
types of, 320
Blood syndrome, 175
See also Liver cancer
Bortezomib
for multiple myeloma, 7
Botanical product, 403
CDER’s botanical review team, 406
See also Herbal products
BPH, see Benign prostatic hyperplasia (BPH)
Brain cancer
with astrocytoma and glioblastoma, 351
integration of TCM with conventional therapies, 364
Bai Hua She She Cao, 365
Bai Jiang Can, 365
Bai Jiang Cao, 365
Ban Xia, 365
Ban Zhi Lian, 365
Chuan Bei Mu, 365
Chuan Xiong, 365
Ci Ji Li, 365
Da Huang Pian, 365
Dang Gui, 365
Di Long, 365
Fang Feng, 365
Fu Ling, 365
Gan Cao, 365
Hai Fu Shi, 365
He Shou Wu, 365
Jin Qian Cao, 365
Jin Yin Hua, 365
Kun Bu, 365
Men Shi Gun Tan Wan, 365
Mu Xiang, 365
Pu Gong Ying, 365
Quan Xie, 365
San Qi Fen, 365
Shan Ci Gu, 365
Sheng Di, 365
Shou Gong, 365
Tian Ma, 365
Tian Zhu Huang, 365
Tu Fu Ling, 365
Wu Gong, 365
Xiao Yao Wan, 365
Ye Ju Hua, 365
Ye Ming Sha, 365
Yun Nan Bai Yao, 365
syndrome differentiation and treatment
Bai Jiang Can, 352
Bai Jie Zi, 352
Ban Xia, 352
Bing Qiu Zi, 352
Chi Shao Yao, 352
Chuan Xiong, 352
Dang Gui, 352
Dan Shen, 352
excessive heat in liver and gallbladder, 358–359
E zhu, 352
Hai Zao, 352
Huang Yao Zi, 352
internal obstruction of dampness and phlegm, 356–358
Kun Bu, 352
liver and kidney Yin deficiency, 355–356
liver deficiency, 359–361
Mu Li, 352
Nan Xing, 352
Qi and blood stagnation, 353–354
San Leng, 352
Shi Chang Pu, 352
Shui Hong Hua Zi, 352
spleen and kidney Yang deficiency, 354–355
Xiang Bei Mu, 352
Yuan Zhi, 352
TCM formulations
Nao Liu Xiao Fang, 362–363
Nao Liu Yi Hao Fang, 363–364
Nao Liu Yi Hao Fang 2, 364
sticky paste for external application, 363
Xiao Liu Tang, 361
Yi Qi Hua Tan San, 361–362
treatment of complications
central fever, 366–367
intracranial hypertension, 366
Yang channels, 351
Brain metastasis, 8
Breast cancer, 52
anthracyclines, 7
carboplatin and paclitaxel, 7
diet therapy
Ju He Ru Mo Mi Yin, 218–219
Pu Gong Ying Yuan Hu Yin, 219–220
Zao Jiao Ci Ju Pi Mi Yin, 221–222
endocrine therapy of Chinese medicine
Er Zhi Wan, 218
Huang Jing, 218
Liu Wei Di Huang Wan, 218
Lu Jiao Fen, 218
Nu Zhen Zi, 218
Xian Lin Pi, 218
Xian Mao, 218
etiology and pathogenesis from TCM perspective
anxiety, 207
Chong Channel, 207
Fu Ke Xin Fa Yao Jue, 207
Ge Zhi Yu Lun, 207
Ren Channel, 207
worry and depression, 207
Yi Zong Jin Jian, 207
historical perspective
Jiao Zhu Fu Ren Liang Fang, 206
syndrome differentiation and treatment principle
accumulated phlegm-heat toxin, 208
accumulation of blood stasis and toxin, 210–211
dual deficiency of Qi and blood, 211
entwinement and obstruction of phlegm and Qi, 209–210
liver depression and Qi stagnation, 209
phlegm-dampness, 208
Qi and blood insufficiency, 208
Qi deficiency, 208
root pathogenesis, 208
soothe liver and regulate Qi, 207
spleen deficiency, 208
surgery-based combination therapy, 208
Yang deficiency, 208
zang-fu viscera, 208
TCM for radiotherapy and chemotherapy side effects
dermatitis, 217
esophagitis, 216
internal heat, Yin deficiency, 215
pneumonia, 215–216
Qi and Yin injury, 215
stomatitis, 217–218
TCM formulations for treatment of complications, 211
Bai Hua She She Cao, 212
Ban Zhi Lian, 212
breast ulcers, 213–214
Bu Gu Zhi, 212
cancer pain, 214
Chen Pi, 212
Chuan Jian Zi, 212
Chuan Xin Lian, 212
Jin Gang Ci, 212
Nu Zhen Zi, 212
Pu Gong Ying, 212
Qing Pi, 212
Sang Zhi, 212
upper extremity swelling, 212–213
Yan Hu Suo, 212
Yi Yi Ren, 212
Breast cancer (cont.)
worldwide incidence
of, 205
Breathing exercises, 379
Burning pain, 159
Bu Zhong Yi Qi Tang formulation, 286

C
CAM, see Complementary and alternative medicine (CAM)
Camptosar®, see Irinotecan/CPT-11
Canadian Intellectual Property Office (CIPO), 530
Canadian Patent Act, 549–550
Cancer-related fatigue (CRF)
concomitant factors of, 372–373
conventional treatments, 373
integrative therapies, 373
biologically based practices, 374–377
energy-based treatments, 383–384
manipulative and body-based practices, 382–383
mind–body medicine treatments, 377–382
whole medical systems, 385–386
physiology of, 372
prevalence of problem of, 371–372
Cancers
pain, CAM for, 394–395
books reviewing effectiveness of, 397
Cochrane reviews, 396
evidence of, 397–398
systematic reviews, 396–397
socioeconomic impact of, 4
staging system for, 5
See also Specific cancers
Capecitabine, see Antimetabolites, DNA poisons
Carboplatin, DNA poisons, 6
and paclitaxel adjuvant chemotherapy, 10
Carcinembryonic antigen (CEA), 192
Catechol I, 50
CDK2, see Cyclin-dependent kinase 2 (CDK2)
CEA, see Carcinoembryonic antigen (CEA)
Celastrol, 412
Cell signalling and diseases
protein-protein interactions in, 646
bioactive natural products, 653
DOS, case for, 660
FAK, 647–652
and GRAF, 647
HDAC, 660–662
human diseases, 647
identification of, 652–655
new technologies to screen for, 655–660
protein kinase C (PKC), 648
and role of naturally derived molecules, 652
trichostatin-A (TSA), 661
Center for Drug Evaluation and Research (CDER), 404
Cephalostatin 1 steroids, 624
Certonardoa semiregularis, 623
Cervical epithelial carcinoma, 52
Cetuximab for colon cancer, 7
Chai Hu Shu Gan San formulations, 246
Chan Su formulation for pain, 198
Chan Su Gao Chinese medicinals, 150
formulation for pain, 198
Chemotherapeutic drugs
microtubular inhibitors, 6
timeline of, 17
Chen Pi formulation, 221
Chlorofusin, 652
Chronic illness therapy–fatigue
functional assessment
fatigue subscale, 376
questionnaire, 379
yoga intervention, 379
Chronic myeloblastic leukemia, 52
Chronic myelogenous leukemia (CML) treatment, 685
Chuan Lian Zi formulation, 219
1,8 Cineole, 58
Cisplatin, DNA poisons, 6
  containing combination doublets
  for NSCLC, 7
Clyste, 151
CML, see Chronic myelogenous
  leukemia (CML)
Coenzyme Q10, 376–377
Cognitive behavioral therapies
  (CBT), 381–382
Colorectal cancer
  etiology and pathogenesis, 136
  formulations and recipes
    Bai She Feng Wei Tang, 144
    Chan Pi Wu Gong Jian,
      144–145
    Jia Wei Si Ni Tang, 148–149
    Jia Wei Zhi Shu Wan, 148
    Leng E Jiang Teng Yin, 146
    Long Shu Weng Lian Tang, 145
    Qing Chang Jie Du Tang,
      142–143
    Qing Chang Xiao Zhong Tang,
      143–144
    Qing Xue Ran Jian Tang, 147
    Shen Ling Shu Jiang Tang,
      149–150
    Xin Jia Xie Xin Tang, 146–147
5-FU, 7
  in geographical distribution, 135
  leucovorin and irinotecan, 7
  syndrome differentiation
    dual deficiency of Qi and
      blood, 139–140
    internal accumulation of
      dampness heat, 136–137
    internal binding of blood stasis
      and toxin, 137–138
    liver and kidney Yin
deficiency, 141–142
    spleen and kidney Yang
deficiency, 140–141
    spleen deficiency and dampness
      obstruction, 138–139
treatment of complications
  ascites, 150–151
  colon obstruction by tumor
    mass, 151
  colon perforation, 152
  pain, 150
Community Plant Variety Rights
  (CVPR), 536
Complementary and alternative
  medicine (CAM), 374, 393,
    396, 398, 424
  approaches for cancer, 31
  drug discovery and development,
    32
  in hemato-oncology
    approach, 67
  modalities, 393–394
    evaluated for cancer pain, 398
  risk management issues, 514
  4 Ts, professional decision-
    making, 514
Computed axial tomography
  (CAT), 4
Concurrent syndromes
  with advanced cancer,
    treatment of
      blood syndrome, 175
      hepatic encephalopathy, 176
      jaundice, 175
  See also Liver cancer
Contaminants, 407
Convention on Biological Diversity
  (CBD), 537
CPT-11, 404
CRF, see Cancer-related fatigue
  (CRF)
Curcuma longa L.
  ayurvedic properties of
    Anuloman, 57
    Doshaghnata, 57
    Guna, 57
    Hikkanigrahana, 57
    Kushthaghna, 57
    Pittarsarak, 57
    Rasa, 57
    Ruchivardhaka, 57
Curcuma longa (cont.)

Shwashara, 57
Verrya, 57
Vipak, 57
Vishagna, 57

biological activity

antioxidant nature, 61
apoptosis in cancer cell lines, 61
carrageein-induced oedema, 60
chronic inflammation, 60
COX2 in human colon tumour cell line, 61
downregulation of transcription factors, 61
free radical scavenging activity, 61
inhibition of lipid peroxidation, 61
ROS and JNK pathway, 61
TNF-α-induced AKT activation, 61

as cancer remedy, 58
carinative for diarrhea, 58
clinical studies

alcoholic extract with, 63
experimental data, 63
external cancerous lesions, 62
modalities of treatment, 63
tolerability, 63
formulations, 60

household spice and herb in India, 57

Krimighna, 58
for liver problems and jaundice, 58
Mootrasangrahaniya, 58
Mootraviranjaniya, 58

phytoconstituents

bisdemethoxycurcumin, 58
curcuminoinds, 58
demethoxycurcumin, 58
diarylheptanoids, 58
hexahydrocurcumin, 58
hexahydrocurcuminol, 58
and metabolites, 59

D

Dachaihu decoction, 175
Dang Gui Long Huai Tang formulations, 246
Defensive Qi, 26
Demethoxycurcumin, 58
Dermatitis, 217
DHT, see Dihydro-testosterone (DHT)
Diarylheptanoids, 58
Didemnin B, 626
Di Huang Wan formulation, 286
Dihydro-testosterone (DHT), 680
Dietary supplements, 403
Di Huang Wan formulation, 286
Dihydro-testosterone (DHT), 680
Distended pain, 159
Distress, 383
Diversity-oriented synthesis (DOS), 660
DMBA-induced papilloma, 42
Docetaxel, 6
DOS, see Diversity-oriented synthesis (DOS)
“Dysphagia”, 85

E
Echinacea, sunflower plant family, 410
components of
butylamides and polyines, 467
dienes and volatile oils, 467
polysaccharides and flavonoids, 467

CYP activity, impact on, 467
drug efflux transporters, 468

Echinacea purpurea preparations, 467
oral bioavailability of Midazolam after intake, 468

Ecteinascidin 743
clinical trials with, 621

EGFR, see Epidermal growth factor receptor (EGFR)

Endocrine therapy of Chinese medicine
Er Zhi Wan, 218
Huang Jing, 218
Liu Wei Di Huang Wan, 218
Lu Jiao Fen, 218
Nu Zhen Zi, 218
Xian Lin Pi, 218
Xian Mao, 218

Endoscopic retrograde cholangiopancreatography (ERCP), 191

Energy
based treatments, 383
conservation, 381–382

EORTC, see European Organization for Research and Treatment of Cancer (EORTC)

Ephedra species
used in traditional medicine, 472–473

Epidermal growth factor receptor (EGFR), 5
anti-EGFR monoclonal antibody, 7
EGFR-TKI gefitinib, 14
EGFR-tyrosine kinase inhibitor, 7
somatic mutations in tyrosine kinase domain, 15

Erbitux, see Cetuximab
ERCP, see Endoscopic retrograde cholangiopancreatography (ERCP)

Erlotinib, see Tarceva

Esophageal cancer
clinical manifestations, 85
esophageal obstruction
Bai Xia Kai Dao Tang, 96–97
Ban Xia Xie Xing Tang, 97
Kai Guan San, 97–98
etiology and pathogenesis
endoogenous and exogenous factors, 86
incidence of, 85
syndrome differentiation and treatment, 86
damage of Yin by heat toxin, 90–91
entwinement of phlegm and Qi, 88–89
kidney Yang insufficiency, 93–94
liver Qi stagnation, 87–88
obstruction of phlegm and blood stasis, 89–90
spleen and stomach deficiency, 92–93
treatment of complications
cancerous pain, 94–96
used formulations
Dong Ling Cao, 103
Er Chen Xuan Fu Tang, 101–102
Hai Zao Mu Li Tang, 102–103
Jian Pi Zi Shen Tang, 99
Kun Bei Wan, 98
Ling Xian Er Cao Tang, 98–99
Shuang Ren San, 103
Shun Qi Ruan Jian Tang, 99–100
Tong You Tang, 101
Zeng Ye Hua Tan Wan, 100–101
Esophagitis, 216
Essence and Qi, theories, 26
    See also Traditional Chinese medicine (TCM)
Etopophos®, see Etoposide
Etoposide, 6, 425
    See also Topoisomerase inhibitors, DNA poisons
European Organization for Research and Treatment of Cancer (EORTC), 12
European Patent Office (EPO), 530
Excision repair crosscomplementation group 1 (ERCC1), 11
E Zhu formulation for pain, 199

F
FAK, see Focal adhesion kinase (FAK)
Fas-associated death domain protein (FADD), 568
Fat Qi, 26
Fire syndrome, 164
Five elements theories, 26
    See also Traditional Chinese medicine (TCM)
Flavonoids, 53, 583
    in cancer prevention, 589
        animal models, 591–592
        antiangiogenic properties, 598
        antimitotic effects, 593–594
        apoptotic effects, 594
        cell signaling, 596–597
        combination with cancer treatments, 599–600
        differentiation, 594–595
        EGCG and GRP78, 596
        epidemiological studies, 593
        in humans, 592–593
        MAP kinase, 597
        multidrug resistance, 595–596
        ovarian cancer, 593
topoisomerase inhibition, 595
    vascular disrupting agents, 598–599
    in vitro antimutagenicity, 590–591
    chemical structures of, 584
        C heterocycle, 585
        fruits and vegetables, 585
classes, 585
        CYP metabolism, 586–587
        daily consumption of, 584
effect on hormone-dependent cancers
        fisetin, 597
genistein, 597
inasmuch, 584
mechanisms of, 590
pharmacological activities
        antiallergic, 588
        antibacterial activity, 589
        anti-inflammatory, 588–589
        antioxidant, 587–588
        antiulcer, 589
        antiviral activity, 589
        cardiovascular diseases, 587
        hepatoprotection, 588
        vascular protection, 588
structures of, 586
toxicity, 600
Focal adhesion kinase (FAK)
    C-terminal domain, 647
    intracellular signalling pathways, 649
    molecular dissection of, 648
        and breast cancer, 651–652
        CHO cell migration, 650
    focal adhesion complex, 651–652
    prostate cancer cell migration, 650
Foot soak, 386
Fu Rong Ze Lan Gao formulation, 214

G
Galluflavanone, 50
Ganluxiaodu pill, 175
Ganmai Dazao decoction, 176

Gan Shu (BL 18) acupoints, 129

Garlic, 410–411
- antiplatelet effect of, 467
- blood pressure, effect on, 466
- constituents of sulfur-containing molecules, 466
- drug metabolism and, 466–467
- hypercholesterolemia, 466
- saquinavir and garlic extract coadministration, 467

Gastric cancer
- role of acupuncture therapy in treatment of, 129–130

Gefitinib, 14

Gemcitabine, 6
See also Antimetabolites, DNA poisons

Genitourinary cancer, 408

Giloy, see Tinospora glabra

Ginkgo, 406, 409
- contents
  - flavonoids and terpenoids, 465
  - glycosides, 465
- and drug interaction, 465
- and efficacy of CYP 2C19 substrates, 465
- formulations
  - age-related macular degeneration, 464
  - antiedemic and antihypoxic, 464
  - antioxidant and antiplatelet, 464
  - asthma and vertigo tinnitus, 464
  - dementia and Alzheimer’s disease, 464
  - diuretic, 464
  - impotence and erectile dysfunction, 464
  - multi-infarct dementia, 464
  - neurotransmitter activity, 465
  - regulation of angiogenesis, 465
- for lymphedema, 414
See also Herbal products

Ginkgo biloba, see Ginkgo

Ginseng, 377
- from Araliaceae plant family, 468
  - cAMP phosphodiesterase activity, 469
  - components of ginsenosides and elutherosides, 469
  - saponins, 469
  - medicinal applications
    - aphrodisiac and antidepressant, 468
    - diabetes mellitus, 469
    - diuretic, 469
    - immune response and cognitive function, 468–469
    - physical performance, 468
    - phytoestrogenic and anticancer, 469
    - sedative and hypnotic, 468
    - stress and homeostasis, 468
    - phytoestrogenic effects, 469
    - thromboxane A2 activity, 469

Glutamine, 409

Glutathione S-transferases (GST), 451
P-Glycoproteins, 411, 451

Glycyrrhiza glabra L.
- for arthritis and viral infections, 474
- for gastric ulcers, 474

Gong Sun (SP4) acupoints, 199

Good agricultural practices (GAP), 406

Good handling practices (GHP), 406

Good manufacturing practices (GMP), 407

Green tea extract, 404

Grossularine
- cytotoxic activity of, 615–616
- structures of, 616

GST, see Glutathione S-transferases (GST)

GTPase regulator associated with FAK (GRAF), 647

Guduchi, see Tinospora glabra

Guipo decoction, 175

Gui Zhi Fu Ling Wan formulations, 246
H

HDAC, *see* Histone deacetylases (HDAC)

Healing touch, 383–384

Healthcare provider responsibility, 499

Heat syndromes, 164

Hematuria, 273

Hemiasterlin peptides, 628
  structures of, 629

Hepatic encephalopathy, 176
  *See also* Liver cancer

Herbal products, 403
  clinical trials, issues and challenges
    CONSORT criteria, 415
    contaminants, 407
    dosage issues, 408–409
    patient recruitment issues, 414
    product-related, 405–411
    quality control in manufacturing, 407
    study design-related, 411–415
    toxicity, 407–408
    hormonal effect of, 408
    pharmacokinetic studies, 410
    to treat precancerous lesions, 413

Herb–drug interactions, 410, 423–424
  cancer cell targets levels and
    angiogenesis regulators, 458
    antiestrogens activity, 458
    apoptotic pathway, 458
    and drug transporters, 458–459
    membrane receptor-mediated signalling, 458
    phosphatases, 458
    prophytotopestrogenic/antiestrogenic activity, 458
    proteasomes, 458
    synergistic/additive effects, 458
    tamoxifen and letrozole activity, 458
    transcriptional regulators, 458
  herbal products use by cancer patients, 426–450
  pharmacology involving
  concentration–response relationship, 451
  CYP enzymes, 451–457
  deviations, 451
  mechanisms of, 452
  monooxygenases, 453
  multiple dosing intervals, 451
  pharmacokinetic and pharmacodynamic monitoring, 451

Herbs as medicine

  Bai Shao, 150, 246
  Bai Shao Yao, 352–353
  Bai Zhu, 150, 246
  Bai Zi, 290
  Ban Lan Gen, 282
  Bing Pian, 214
  Bin Lang, 151
  Bu Gu Zhi, 289
  Cheng Qi Tang, 151
  Chen Pi, 289
  Che Qian Zi, 151, 246, 255
  Chi Shao, 152
  Chuangshanjia, 165
  Chuan Lian Zi, 290
  Chuan Shan Jia, 255
  Chuan Wu, 214
  Chuan Xiong, 214, 290
  Chuan Xu Duan, 289, 291
  Da Huang, 151–152, 255
  Dang Gui, 255, 283, 290
  Dan Shen, 283
  Dong Gua Zi, 152
  Du Huo, 165, 290
  Du Zhong, 353
  E Jiao, 283
  E Zhu, 246, 255
  Fang Feng, 290
  Fo Shou, 289
  Fu Ling, 151, 246
  Fu Zi, 151, 246, 289–290
  Gan Cao, 151, 214
  Gan Cao Shao, 255
  Gan Sui, 246
  Gao ben, 290
  Ge Gen, 290

Subject Index
Gou Ji, 289
Gou Qi Zi, 290
Gu Lou, 290
Gui Yuan Rou, 283
Gui Zhi, 150, 246, 290
Gu Sui Bu, 289
Haifengteng, 165
Hong Hua, 152, 255
Hong Zao, 283
Huang Bai, 151
Huang Jing, 283
Huang Lian, 282
Jiang Huang, 290
Jiao San Xian, 289
Ji Xue Teng, 283
Lian Qiao, 282
Liu Yi San, 255
Lu Dou Yi, 353
Luoshiteng, 165
Ma douling, 166
Ma Huang, 214
Mang Xiao, 151, 255
Ma Qian Zi, 291
Mo yao, 290
Mu Dan Pi, 152
Mugua, 165
Niu Qi, 255
Niu Xi, 291
Nu Zhen Zi, 353
Pu Gong Ying, 282
Qeilngxian, 165
Qiang Huo, 290
Qing Pi, 214
Qinjiao, 165
Qin Jiao, 290
Rou Cong Rong, 289
Rou Gui, 255, 289
Ruxiang, 290
Sang Zhi, 290
San Leng, 255
San Qi, 289–290
San Qi Fen, 283
Sanzhi, 165
Shan Dou Gen, 282
Shan Zhu Yu, 353
Shao Yao, 151
Sha Shen, 283
She Gan, 282
Sheng Di, 282–283
Sheng Di Huang, 255, 352
Sheng Huang Qi, 282–283
Tan Xiang, 290
Tao Ren, 152, 255
Tu Si Zi, 289
Wang Bu Liu Xing, 290
Wei Ling Xian, 290
Wu Gong, 289
Wu Shao She, 289
Xiang Fu, 290
Xi Xin, 214, 290
Xi Yang Shen, 283
XuchangQIn, 165
Yin Hua, 282
Yin Yang Huo, 289
Yuan Shen, 282
Yu Jin, 290
Ze Xie, 151
Zhang Nao, 214
Zhe Xie, 246
Zhi Qiao, 151, 290
Zhi Shi, 151
Zhu Ling, 151, 246, 255
Zi He Che, 283
Herceptin, see Trastuzumab
Hexahydrocurcumin, 58
Histone deacetylases (HDAC), 660–661
homology model of, 662
inhibitors, 7
study in, 662
Hong Hua formulation for pain, 199
Hong Tong plant camptothecin, 174
Hormone-refractory prostate cancer (HRPC), 671–672
HRPC, see Hormone-refractory prostate cancer (HRPC)
Huangbo for lower-jiao heat, 165
Huanglian for gastrointestinal heat, 165
HuangQin, 165
for upper-jiao lung heat, 164–165
Human umbilical vein epithelial cells (HUVEC), 42
Hu Yin Jin Qu Tang formulation, 199
Hycamtin®, see Topotecan
Hydroxyflutamide, 676
Hypnosis, 378

I
IALT, see International Adjuvant Lung Cancer Trial Collaboratory Group (IALT)
Ifosfamide, DNA poisons, 6
Imatinib, 411
Immumod®, 46, 48
Immunopurification coupled to mass spectrometry (IP-HTMS), 652
isolated proteins, 654
peptide mixtures, 654

India
Ayurveda
herbs and natural products, 32
Indian ginseng, 38
plants and, 33
history of cancer in CAM
Agastya Nadi, 34
Arbuda, 34
Ashwagandharishta, 33
Atharva Veda, 34
ayurvedic taxonomy, 34
Bhrigu-Samhita, 32
doshas and dhatu, 34
granthi and gulma, 34
Heerak Bhasma, 33
sushruta, 34
Vasant Kusumkar Rasa, 33
Withania somnifera, 33
Yogarajguggulu, 33
medicinal plants
guggulu, 32
reverse pharmacology, 32
See also Ayurvedic medicine

Indigenous Peoples Rights Act (1997), 539
InspireHeath
cultural values
authenticity and integrity, 507
open communication, 507
personal growth, 508–509
self-responsibility, 506–507
teamwork, 507

Intellectual property, 529
International Adjuvant Lung Cancer Trial Collaboratory Group (IALT) trials, 10–11
International Union Against Cancer tumor/node/metastasis schema, 5
International Union for Protection of New Varieties of Plants (UPOV), 537
Invention patents, 531
claims, 532–533
PCT applications and process, 533–535
provisional patent applications, 535
See also Patents
Investigational New Drug (IND), 406–407
Iressa, see Gefitinib
Irinotecan, 6–7, 411
See also Topoisomerase inhibitors, DNA poisons
Irinotecan/CPT-11, 424–425

J
Japanese Patent Office (JPO), 530
Jaundice formulation
Chuan Shan Jia, 200
Huo Xue Tong Luo Tang, 200
Hu Yin Jin Qu Tang, 199
Hu Zhang, 200
Jin Qian Cao, 200
Shan Zha, 200
Shen Qu, 200
Yin Chen, 200
Zao Jiao Ci, 200
Jeediflavanone, 50
Jian and Jie, 165
JiaoGan (AH6a) acupoints, 199
Jing Ling Zi formulations, 247
Jin Ke Huai Er Chong Ji formulation, 202
Jojoba oil, 386
Ju He formulation, 218

K
Kidney cancer
acupuncture
acupoint injection, 307
assistant points, 306
auricular acupoints, 306–307
chief points, 306
lumbago, 307
case studies, 309–317
chemotherapy and integration of TCM with, 282
clears heat and detoxifies body, 282
nourishes Qi and blood, 282–283
nourish liver and kidney, 284–285
strengthens spleen and harmonizes stomach, 283–284
external TCM medicine
Ai Tong San, 308
incidence of, 271
integration of TCM with surgery
Bao Yuan Tang, 280
Ba Zhen Tang, 280
benefiting Qi and removing toxin, 281
Liu Wei Di Huang Tang, 280
metastasis risk, 280
Qi and consolidating exterior, 281
Shi Quan Da Bu Tang, 280
Si Jun Zi Tang, 280
spleen and stomach function regulating, 281
Zeng Ye Cheng Qi Tang formulation, 281
massage, 307–308

nourishing and nursing, diet and
after surgery, 309
during chemotherapy, 309
for patients with advanced kidney cancer, 309
during radiotherapy, 309
before surgery, 308
radiotherapy and TCM, 285
syndrome differentiation and TCM therapeutic approaches
accumulation and binding of dampness-heat, 275–276
deficiency of liver and kidney Yin, 275
dual deficiency of Qi and blood, 278–279
dual deficiency of spleen and kidney, 273–274
hyperactivity of heart fire, 277–278
internal obstruction of blood stasis, 276–277
linger of evil-toxin after cancer being attacked, 279–280
syndrome differentiation and treatment
anemia, 294–295
chronic renal failure, 291–292
dual deficiency of kidney Yin and Yang, 286–287, 297–298
fever, 299–303
kidney deficiency and blood stasis, 298
liver and kidney Yin deficiency, 296–297
Qi and blood deficiency, 287–288
Qi and blood stasis, 288–291
Qi and Yin deficiency, 292–293
spleen and kidney Yang deficiency, 292, 295–296
Kidney cancer (cont.)
  Yin and Yang dual deficiency, 293–294

TCM formulation
  Bai Hua She She Cao, 304
  Bai Mao Gen, 304
  Ban Bian Lian, 303–304
  Ban Zhi Lian, 304
  Ba Yue Zha, 305
  Chi Fu Ling, 304
  Chi Xiao Dou, 304
  Da Ji, 304–305
  Dao Dou, 304
  Fu Fang Long She Yang Quan Tang, 304
  Hai Jin Sha, 304
  Hei Dou, 303–304
  Huai Hua Tan, 304
  Huai Jiao, 303
  Huang Bai, 304
  Huang Yao Zi, 304
  Jin Qian Cao, 303–304, 306
  Ma Bian Cao, 303
  Pu Huang Tan, 304
  Qing Teng, 305
  Qu Mai, 303, 306
  Sheng Di, 304
  Sheng Di Tan, 305
  Sheng Yi Yi Ren, 303–304
  Shi Shang Bai, 305
  Shi Wei, 303
  Xia Ku Cao, 305
  Xiao Ji, 304–305
  Xue Jian Chou, 304–305
  Ye Pu Tao Gen, 304
  Yi Yi Ren, 304–305
  Zhu Ling, 304–305

TCM pathogenesis
  deficient and excessive syndromes, 272–273
  emaciation and anorexia, 273
  emotional disorder, 272
  hematuria, 273
  improper diet, 272
  Qi stagnation and blood stasis, 272
  senility and weak body constitution, 272
  spleen and liver, 272
  spleen dysfunction, 272
  Yin and Yang deficiency, 272
  treatment of complications bone metastasis, 285–286

L
  LACE, see Lung Adjuvant Cisplatin Evaluation (LACE)
  LBD, see Ligand-binding domain (LBD)
  Lectin-standardized mistletoe extract, 375

Legal issues, cancer treatment in, 514
  access to information, 515–516
  alternative treatments, use of, 524
  ascertain risks associated with, 522
  category of interest, 515
  claims
    for damages, 519
    for malpractice, 519, 523
    for negligence, 519–520, 523
  contacted for information, 516
  cross-border considerations, 519
  dealing with use of diagnostic tools, 522–523
  dissemination of information, 516
  evolution of science and health care, 525
  glass jaw principle, 518–519
  health care practitioner, to meet standards, 526
  informed consent, 521
  with full disclosure, 518
  and insurance company, 524, 527
  intentional torts, 519–520
  intervention of homeopathic remedies, 523
  issue of confidentiality, 516
  knowledge of health care, 521
  media reporting on, 527
  nonlife-threatening interaction, 518
patient and practitioner, relationship of, 515–516, 518, 526
proprietary rights, 514
questions, 515
Reibl vs. Hughes, 521
standard of proof, 517
statutorily requirement, 521
third party pay, 516, 524, 527
Leucovorin, 7
Levocarnitine supplement, 375–376
Lewis lung carcinoma, 52
Lian Ling Ting Li Tang formulation, 200–201
Ling gui shu gan decoction, 166
Lipoteichoic acid (LTA), 619
Liver cancer, 153
concurrent syndromes with advanced cancer, treatment of, 175–176
ascitis, 161
bleeding, 160–161
cancerous fever, 162
coma, 161–162
hypertrophic osteoarthropathy, 162
jaundice, 161
multiple neuropathy, 162
paraneoplastic syndrome, 162
thyropathy, 162
medicines used for addie injection, 173–174
arsenious acid injection, 173
Baishao, 172
Banmao, 172
Banzhilian, 172
Bayuezha, 172
Chuipengcao, 172
Dahuang Zhechong pill, 172–173
dry Chanpi, 172
HCPT, 174
huachansu injection, 174
HuangQI, 172
Huzhang, 172
kanglaite, 174
Lianhua tablet, 173
Qinggan Xiaotong Pill, 173
Qiyeyizihhua, 172
Sancigu, 172
Wugong, 172
Xiaoyu Yigan tablet, 173
Xuejie, 172
pathogenesis from TCM perspective
blood stasis, 155–156
body accumulation of toxin-heat, 156–157
deficiency of vital QI, 157
evil factors and healthy energy in cancer, 157–158
phlegm-damp agglomeration, 156
QI stagnation, 154–155
Yin and Yang concept, 154
TCM-based diagnosis of based on signs, 159
deficiency syndrome, 160
emaciation, 160
inflammatory type, 158
poor appetite, 159
sclerosis type, 158
simple type, 158
TCM therapeutics principles acupuncture treatment, 178–179
and/or chemotherapy, 163
dietary therapy, 181–182
external therapeutic methods, 177–178
interventions, 164–166
management, 163–164
Qigong therapy, 179–180
TCM treatments deficiency of liver and kidney Yin, 171–172
liver heat and blood stasis, 170
liver heat and phlegm toxins, 170–171
liver stagnancy and kidney deficiency, 169–170
Subject Index 709
Liver cancer (cont.)
QI stagnation and blood stasis, 166–167
spleen deficiency and phlegm stagnancy, 168–169
spleen deficiency and QI stagnation, 167–168
Liver toxicity, 408
Lobectomy, 8
See also Non-small cell lung cancer (NSCLC)
Longdan Xiegan decoction, 175
LTA, see Lipoteichoic acid (LTA)
Lung Adjuvant Cisplatin Evaluation (LACE), 10
Lung cancer
in China, 5
current therapy for, 7–8
algorithm, 13
combination treatment, 16
planning, 11
strategy, 12
therapeutic plateau, 14
treatment paradigm for, 9
trials, 10, 15
in developed world, 5
in developing countries, 5
incidence, 5
Lung Cancer Study Group clinical trial, 8
Lycopene, 409
Lymphocytes, 383

M
Marine bioactive
alkaloids, 614, 619, 621
adriamycin, 622
with antitumor activity in clinical trial, 615
biological activity, 615
β-carbolines, 616
ecteinascidin 621, 743
α-galactosylceramide, 619
grossularine, 615–616
KRN-7000, 619
lamellarins, 617–618

LTA, 619
MDR, 619
ningalin B hexamethyl, 617, 619
permethyl storniamide A, 619
plakortamines, 616–617
Plakortis nigra, 616
psammapin A, 619, 621
spisula polynyma, 619
spisulosine, 619, 621
storniamide A, 619–620
and trichostatin A, 619, 621
peptides
BEL-7404 human hepatoma cell line, 630
didemnin B, 626–627
hemiasterlin, 628–629
phakellistatin, 630–631
porifera cyclic octapeptides, 630–631
scleritodermine A, 628
tasipeptins A and B, 626–628
treatment with HTI-286, 629–630
steroids
agosterol A, 623
cephalostatin 1, 624
Cetonardoa semiregularis, 623
dimeric marine-derived, 623–624
P-glycoprotein 170, 623
plant-derived, 623
ritterazine A, 625
squalamine, 625–626
sterol, 622
Massage therapy, 382–383
MCA-induced fibrosarcoma, 42
MDR, see Multidrug-resistant (MDR)
Medicinal plants for cancer therapy, 558
active molecules, isolation of, 561–562
alkaloids molecular modes of action
ABC-transports, 569–570
apoptosome, 568
Bcl-2 gene, 569
Catharanthus roseus, 568
Colchicum, 568
CYPs, 569
cytotoxic interactions of, 564–566
detoxifying enzymes and proteins, 569
DNA, 563, 566–567
FADD, 568
Huperziaserrata, 569
microtubules, 568
paclitaxel, 568
P-glycoprotein, inhibition, 570
ROS, 569
Taxus brevifolia, 568
telomerase, 567
herbal medicine, 559
isolated natural products, use, 562
natural products, 560, 562
pharmacogenomics
ABCD-transporter, 575
COMPARE analyses, 571, 573
drug efflux/detoxification mechanisms, 570
and hierarchical cluster analyses, 571, 574
microarray analyses, 575
mRNA expression data for, 573
NCI, 571, 573
Spearman’s rank correlation test, 571
steric complexity, 561
Vinca alkaloids, 560
Melanoma, 412
6-Mercaptopurine, chemotherapeutic drugs, 52
Metastatic NSCLC, 7
Methotrexate, chemotherapeutic drugs, 52
Metoclopramide, 413
Mind–Body Medicine, 377–378
Mindfulness-based stress reduction (MBSR) program, 378
Mitochondria-mediated cytochrome C, 42
Mitogen-activated protein kinase (MAP kinase), 597
Mitomycin-C, chemotherapeutic drugs, 52
Modern cancer therapy, 5
modern medicine, 559
paradigm of staging system, 5
tumor/node/metastasis schema, 5
Modified Da Huang Mu Dan Tang, 152
Modified Shen Tong Zhu Yu Tang formulation, 289
Mo Yao formulation, 218
Multidrug-resistant (MDR) cancer cell lines, 619
Multimodality therapy, 12
Multiple myeloma, 7
Mutated androgen receptors mining natural products antiandrogen compounds, 679, 681
AR antagonists, 681
compound 13, binding mode, 684–685
Cryptomeria japonica, 680
curcumin and β-ionone, design, 683
DHT, 680
diterpenes 1–3, 679
human epidemiological and animal studies, 682
indole-3-carbinol, 680
luciferase reporter assays, 683
molecular modeling and structure-based drug design, 680
Piper cubeba L. seeds, 680
structural models of AR LBD, 681–682
troplone-related compound, 680
N
Nallaflavanone, 50
National Biodiversity Authority (NBA), 538
National Cancer Institute (NCI), 571
National Center for Complementary and Alternative Medicine (NCCAM), 374
Natural killer cells, 383
Nausea, 383
Neiguan (PC6) acupoints, 150
Nei Guan (PC6) acupoints, 247
Nonpharmacological management, 381
Non-physical healing environment practitioner/patient interactions, 505
staff interactions, 506
Non-small cell lung cancer (NSCLC) cisplatin-containing combination doublets for, 7
treatment paradigm for, 9
treatment strategy for algorithm, 13
anatomic segmentectomy, 8
antiangiogenesis therapy, 15
bevacizumab with carboplatin + paclitaxel, 15–16
CALGB 9633 clinical trial, 10
carboplatin/paclitaxel adjuvant chemotherapy, 10
chemoradiotherapy, 13
chemotherapeutic drug, timeline of, 17
clinical and pathologic TNM stages, 8
cytotoxic standard chemotherapy, 15
DNA repair ERCC1, 11
EGFR-TKI + chemotherapy studies, 14
EGFR-TKI gefitinib, 14–15
lobectomy, 8
Lung Cancer Study Group clinical trial, 8
meta-analysis, 10
multimodality therapy, 12
platinum-based doublets palliative chemotherapy, 14
pneumonectomy, 8, 12–13
PORT trials, 12
p53 protein expression and, 11
SEER database, 12
stages and planning, 11–13
surgical results, 10
survivals for, 8
therapeutic plateau, 14
thoracic lymphadenectomy, 8
thoracic radiotherapy, 10, 12 trials, 10
trimodality therapy, 13
UFT use, 10–11
Noval protein-protein interactions, identification
BRET and FRET, 654
IP-HTMS, 652
peptide mixtures, 654
in yeast and human, mapping, 655
NSCLC, see Non-small cell lung cancer (NSCLC)
Nuclear factor kappa B (NF-κB) binding to DNA, 42
Nutritive Qi, 26
O
Oncovin®, see Vincristine
Ouch point, 150, 247
Ovarian cancer
history from TCM perspective
Jing Yue Quan Shu, 224
Qi reverse and blood retained, 224
Zhu Bing Yuan Hou Lun, 224
incidence of, 223
syndrome differentiations and treatment
dampness-heat and toxin stagnation, 227–228
dual deficiency of Qi and blood, 233–234
phlegm-dampness accumulation and coagulation, 229–230
Qi stagnation and blood stasis, 226–227
spleen with Qi deficiency, 232–233
Yin deficiency and internal heat, 230–231
Yin deficiency of liver and kidney, 231–232

TCM-based etiology and pathogenesis
improper diet, 225
internal injury by seven irregular emotions, 225
Qi stagnation and blood stasis, 225

TCM formulations
Ban Zhi Hua She Tang, 238
Chuan Shan Jia San, 234–235
Chuan Xin Lian injectable, 241–242
Ding Xiang A Wei San, 239
Fu Zheng Jie Du San Jie Yin, 238–239
Hua Liu Wan, 240
Ji Sheng Da Huang Tang, 236–237
Qing Rei Xiao Liu Jian, 239–240
San Ren Tang, 241
Shi Shang Bai injectable, 241
Shuang Shi Tang, 236
Tao Hong Si Wu Tang Jia Wei, 237–238
Tian Hua Feng desiccant, 242
Wu Mei Xiao Xia San, 235

TCM treatment and integrative conventional, 242

Ce Bai Ye, 245
Chen Pi, 245
dual deficiency of Qi and Yin, 244
Fu Ling, 245
Huai Hua Tan, 245
Jiang Ban Xia, 245
Lu Gen, 245
Mai Men Dong, 245
Qi deficiency, 243–244
radiotherapy and chemotherapy, 245
therapeutic effect, 243
Yin-deficiency effect, 244
Yi Yi Ren, 245
Zhi Qiao, 245
Zhu Ling, 245
Zhu Ru, 245
treatment of complications
abdominal pain, 247
malignant ascites, 246
Oxaloplatin, DNA poisons, 6
Oxidative stress damage, 377

P
Paclitaxel, 6, 404, 425
induced neutropenia, 43
Panax ginseng, 411
Pancreatic cancer, 7
clinical manifestations and diagnosis in TCM
abdominal CT scans, 191
abdominal pains and swelling, 189
blood tests, 191–192
CEA levels, 192
Courvoisier’s sign, 190
diarrhea and constipation, 189
epigastirc discomfort, 189
ERCP, 191
fatigue and poor appetite, 189
fever, 189
lumps, 189–190
nausea and vomiting, 189
seroenzyme tests, 192
urine BT-PABA tests, 192
waist and back pain, 189
weight loss and jaundice, 189–190

etiopathogenesis from TCM perspective, 187–189
syndrome differentiation and treatment in TCM
Bai Hua She She Cao, 196
Bai Mao Teng, 198
Bai Xu Cai, 195
Pancreatic cancer (cont.)

Bai Zhu, 193
Ban Bian Lian, 196
Ban Xia, 193
Ban Zhi Lian, 193
Ba Yue Zha, 195
Chao Gu Ya, 194, 197
Chen Pi, 193
Che Qian Zi, 197
Chuan Jian Zi, 193
Chuan Lian Zi, 195–196
Chuan Shan Jia, 195
Da Fu Pi, 194
Da Huang, 193–194
Danshen and Eshu, 196
E Zhu, 193
Fu Ling, 193, 198
Fu Zi, 197
Ge Xia Zhu Yu Tang, 195
Gua Lou, 194, 196
Huang Jing, 193, 196
Huang Qi, 194
Hu Zhang, 193–194
Ji Nei Jin, 194, 196–197
Jin Yin Hua, 196
Ji Xue Teng, 198
modified Ge Xia Zhu Yu Tang, 194
modified Wu Ling San, 197
modified Yi Guan Jian, 195–196
modified Yin Chen Hao Tang formulation, 192–193
Mu Xiang, 193–194, 198
Pu Huang, 194
Qian Niu Zi, 197
Qian Shi, 197
Qi deficiency and dampness stagnation, 196
Qi stagnation and blood stasis, 193–195
Ren Shen, 197
San Leng, 194
Shen Qu, 193

Shi Jian Chuan, 198
Shu Da Huang, 193
Shu Di Huang, 197
Tai Zi Shen, 196
Teng Li Geng, 195
Wu Ling Zhi, 194
Wu Yao, 195, 198
Xian He Cao, 194
Yi Guan Jian, 196
Yin and Yang deficiencies, 197
Yin Chen, 193–194
Yin deficiency and toxic heat, 195
Yi Yi Ren, 193, 198
Yuan Hu, 193, 195
Yu Jin, 193
Ze Xie, 198
Zexie and Mabiancao, 196
Zhe Bei, 195
Zhi Gan Cao, 198
Zhi Mu, 196
Zhi Zi, 193
Zhu Ling, 193, 198
Zi He Che, 197
Zu Ru, 193

TCM formulations
Bie Jia Jian Wan, 201–202
Da Huang Zhe Chong Wan, 201

TCM treatment
historical description, 187
knowledge of, 186

TCM treatment complications
ascitis, 200–201
jaundice, 199–200
pain, 198–199

worldwide incidence of, 185

Patents
challenges
interferences (United States), 546–547
oppositions/nullity actions, 547
re-examinations and reissue, 547–548
infringement
Canada, 549–550
Europe, 549
United States, 548
offices, 530
requirements, 539
inventive step/
nonobviousness,
543–545
novelty, 541–543
support in specification and,
545–546
types of
plant patent, 535–536
sui generis system, 536–539
utility/invention, 531–535
Patient–physician relationship, 497
environment, 503
generalizations, 501–502
healing and, 498
paradoxical nature of, 501
responsibility for, 499–500
supporting environment, 509
healthcare provider responsibility, 499
InspireHealth, 504
lifestyle recommendations, 502
non-physical environment
practitioner/patient
interactions, 505
staff interactions, 506
physical environment, 505
religious teaching
love, compassion and
empathy, 498
sympathy and empathy, 500–501
Peptides
didemnin B, 626
structures of, 627
hemiasterlin, 628
structures of, 629
phakellistatin, 630
structures of, 631
porifera cyclic octapeptides,
630–631
scleritodermin A, 628
tasipeptins A and B, 626, 628
structures of, 627
Permethyl storniamide A peptides, 619
Phakellistatin peptides, 630
structures of, 631
Pharmacovigilance and herbal
products
ADR reporting systems, 459
African potato, 470
benefit and risk associated, 460
BPH symptoms, 471–472
database, 460
dietary nutrients, 475–476
Drug Monitoring Program of
WHO, 459
Echinacea, sunflower plant
family, 467–468
garlic use, 466–467
Ginkgo biloba use, 464–466
ginseng, 468–469
indications, 459
manufacturing, 460
medicinal herbs susceptible with
drug pharmacology,
472–475
nomenclature worldwide, 459
Pygeum, 470
Saw palmetto, 470
stinging nettle, 470
St John’s wort, 462–464
α-Phellndrene, 58
Phlegm-damp, 156
Physical healing environment, 505
Pi (CO13) acupoints, 199
Piper fatique scale, 381
Piper methysticum
eextract
anxiolytic and sedative, 473
kavalactones, 473
Pishu (BL 20) acupoints, 130
Plant Breeder’s Rights for plant
varieties, 536
Plant patents, 535–536
Plant Variety Protection Act
(PVPA), 536
Platinum-based doublets palliative
chemotherapy, 14
Pneumonectomy, 8
See also Non-small cell lung cancer (NSCLC)
Pneumonia, 215–216
Polarity therapy, 384
Polyphenon, 404
Postoperative radiotherapy (PORT) trials, 12
p53 protein expression and NSCLC, 11
Pemetrexate, 6
See also Antimetabolites, DNA poisons
Probiotics, 408
Profile of mood states, 377–378, 381, 383
Proprietary rights, 514
Prostate cancer, 672
androgen ablation, 673
etiology and pathogenesis
excessive emotion and stress, 250
phlegm dampness, 250
Qi stagnation, 250
water and body fluid retention, 250
weak constitution, 250
Yang Qi, 250
incidence of, 249
syndrome differentiation and treatment, 250
dampness heat accumulation, 251–252
internal binding of blood stasis, 252–253
kidney Qi deficiency, 253–255
TCM formulations, 267–269
Bu Yuan Tiao He Tang, 258–261
Jie Re Tong Lin Fang, 257
Liu Wei Di Huang Tang, 262–263
Long She Piao Xiao Tang, 264
Qing Re Tong Lin Fang, 258
Shen Qi Xian Rong Tang, 261–262
Tu Fu Ling, 265–266
Zhi Qian Lian Xian Ai Fang, 264–265
Zhi Tong Fang, 263–264
Zhong Jie Fen Cha, 265
treatment of complications
acupoints stimulation, 256
low urinary tract obstruction, 255
Prostate-specific antigen (PSA), 672, 677
HRPC, 673
nonsteroidal antiandrogens used in, 673
Proteasome inhibitor, 7
Protein-bound polysaccharide extract (PSK), 412
Protein-protein interactions in bioactive natural products, 653
DOS, case for, 660
FAK, 647–652
and GRAF, 647
HDAC, 660–661
homology model of, 662
study in, 662
human diseases, 647
identification of, 652–655
new technologies for screening, 655–660
CDK2, 659–660
fragment-based lead discovery, 657
functional protein microarrays, 655–656
NMR spectroscopy, 657, 659
protein–ligand crystallography, 659
small-molecule microarrays, 656–658
X-ray crystallography, 659–660
protein kinase C (PKC), 648
and role of naturally derived molecules, 652
trichostatin-A (TSA), 661
Protein tyrosine phosphatase 1B (PTP-1B), 659
PSA, see Prostate-specific antigen (PSA)
Pu Gong Ying formulation, 219–220

Q
QCAR, see Quantitative-composition-activity relationship (QCAR)
Qigong therapy, 179–180
Qi Gui Shan Jia Tang formulation, 213–214
Qing Pi formulation, 221
Qingre Dihuang decoction, 175
Qi Ye Yi Zhi Hua formulation for pain, 198
Quantitative-composition-activity relationship (QCAR), 677–678

R
Radiation therapy, 6
Randomized controlled trial (RCT), 406
Reactive oxygen species (ROS), 569
Recognition of Forest Rights (2006), 538
Referred pain, 159
Reflexology, 386
Reiki treatments, 384
Relaxation, 383
and breathing exercise, 379
therapy, 381
Renshen Biejia decoction, 176
Restorative yoga (RY), 380
Ritterazine A steroids structure, 625
ROS, see Reactive oxygen species (ROS)
Ru Xiang formulation, 218
Ruyi Jinhuang powder, 177

S
Salvia miltiorrhiza extract
for cardiovascular diseases, 474
San Jiao (CO17) acupoints, 199
San ren decoction, 166
San Yin Jiao (SP6) acupoints, 150, 199, 247, 256
Saw palmetto, 470
SCLC, see Small cell lung cancer (SCLC)
Scleritodermin A peptides, 628
Scorbing pain, 159
Semecarpus anacardium L.
aflatoxin B1-induced hepatocellular carcinoma for, 52
Amura recemososa with, 53
ayurvedic properties
Adhman, 49
Arsha, 49
Grahani, 49
karmas with, 49
Krumi, 49
laghu, snigdha, tikshna and ushna gunas, 49
madhur and kashaya ras, 49
madhur vipak, 49
for rheumatic diseases and anticancer activity, 49
Snitra, 49
ushna veerya, 49
Vardhaman Prayog, 49
Vran, 49
Bhallatak, 48–49
biological activity, 50
B-16 melanoma and glioma, 52
clinical studies
Anacardin Forte, 53
anticancer remedies, 53
Vad’s findings, 54–55
cytotoxic effects in human tumour cell lines, 52
formulations
amrit bhallatk avaleha, 50
bhallatak ghrutam, 50
bhallatak gud, 50
bhallatak haritaki, 50
bhallatak lepa, 50
bhallatak Parpati, 50
Semecarpus anacardium L. (cont.)

*bhallataksav*, 50
*bhallatak tailam*, 50
*narsimha choorna*, 50
*sanjeevani vati*, 50
*shodhan*, 50
*suranvatak*, 50
fruit kernel use, 49
*Glycyrrhiza gabra* with, 53
*Godambi*, 49
inhibitory activity cyclooxygenases, 53
phytochemistry
oil, 50
phenolic compounds, 50
phyto-constituents of, 51
P-388 lymphocytic leukemia for, 52
recommendations and caution
anticancer properties, 56
potency and utility of medicine, 57
Sidha medicine, 52
toxicity studies
adverse alterations, 56
extract administration, 56
Tween 80, 56
Semicarpusflavanone, 50
Semicatetepin, 50
Sesquiterpenes, 58
Sheng Chuan Wu formulation for pain, 198
Shen Ji San formulation, 214
ShenMen (TF4) acupoints, 199
*Shen Qi Wan* formulation, 286
*Shen Que* (CV 8) acupoints, 130
Shihui pulvis, 175
Shi pi decoction, 166
*Silybum marianum*
eextract for liver damage, 474
Sleep
hygiene, 381
promotion plan, 381
restriction, 381
Small cell lung cancer (SCLC)
cisplatinum-based combination chemotherapy, 8
median survival of, 8
randomized clinical trials, 8
stage I, 8
survival rate, 8
treatment for
cisplatin/etoposide, 7–8
prophylactic cranial radiation, 8
Spider telangiectasia, 160
Spisulosine, 619
structures of, 625
Squalamine steroids, 626
structures of, 625
Steroids
agosterol A, 623
structure of, 623
cephalostatin 1, 624
P-glycoprotein 170, 623
plant-derived, 623
ritterazine A, 625
structure of, 625
squalamine, 626
structures of, 625
sterol, 622
St. John’s wort (SJW), 410–411, 460
adverse effects on drug pharmacology, 463
extracts contents
anti-HIV agents, 463
anti-inflammatory agents, 463
antimicrobial agents, 463
cardiovascular drugs, 463
central nervous system agents, 463
esential oils, 462
flavonoids, 462
hypoglycaemic agents, 463
immunomodulating agents, 463
as inhibitors of CYP enzymes, 462
naphtodianthrones, 462
oral contraceptives, 463
phenolic acids, 462
phloroglucinols, 462
proton pump inhibitors, 463
respiratory system agents, 463
statins, 463
induction of P-gp drug, 463
irinotecan and, 464
as oil and tablets, 462
as powder and tea infusion, 462
taxol and etoposide, 464
Stomach cancer
case studies, 203–204
dual deficiency of spleen and kidney, 108
etiology and pathogenesis
Qi deficiency, 106
stagnated Qi, 107
Fuyang pulse, 106
inadequate diet, 107
irregular emotion, 108
role of acupuncture therapy in treatment of gastric cancer, 129–130
stress, 108
syndrome differentiation and treatment, 108
deficient-type cold in spleen and stomach, 114–115
dual deficiency of Qi and blood, 116–117
entwinement and obstruction of phlegm and Qi, 111–112
liver and stomach, disharmony of, 109
Qi stagnation and blood stasis, 110–111
spleen and stomach Qi deficiency, 112–113
stomach Yin deficiency, 113–114
TCM recipes for
Ban Xia Xie Xin Tang combined with Si Jun Zi Tang, 124–125
Chai Hu Shu Gan Tang combined with Xi Shu Jian, 118
Fu Fang San Si He Ji, 128–129
Fu Zheng Jian Du Fang, 125–126
Hua Liao Zeng Min Fang, 126–127
Kang Ai Ling, 124
Liu Jun Yi Yi Ren Tang, 119–120
modified Zhi Pu Liu Jun Zi Tang, 120–121
prognosis, 130–131
Sheng Xue Fang, 127–128
Sheng Xue Tang Plus and Minus, 117
Tong You Tang, 122–123
Yi Qi Fang Du Tang, 121–122
Yi Qi Jian Pi Tang, 123–124
Yi Qi Zhi E Tang, 125
Zhi Wei Ai Fang, 118–119
treatment of complications
ascites, 132
dumping syndrome, 132–133
gastric outlet obstruction, 132
hemorrhage, 131
Stomatitis, 217–218
Storniamide A, 619
structures of, 620
Stranguria, 319
Structure–activity relationships (SAR), 657, 659
Sui generis system for protection, 536
Brazil, 537–538
India, 538
Peru, 538
Philippines, 539
Superior sulcus tumor, 13
Sushruta-Samhita, 34
T
T2 Adenocarcinoma, UFT use and, 10–11
Tai Chong (LR3) acupoints, 129, 199
Tao Hong Si Wu Tang formulations, 247
Tarceva
for metastatic NSCLC and pancreatic cancer, 7
Tasipeptins A and B peptides, 626, 628
structures of, 627
Taxol®, see Paclitaxel
TCM, see Traditional Chinese medicine (TCM)
Teniposide, 425
Tetrahydrocurcumin, 58
Therapeutic implications
  AR pan-antagonists, 686
  CML, treatment of, 685
  EGFR kinase inhibitors, 686
Therapeutic massage, 383
Thoracic lymphadenectomy, 8
  See also Non-small cell lung cancer (NSCLC)
Three-Step Analgesic Ladder Therapy, 247
Tianluo extract, 177
Tian QI ejiao syrup, 175
Tibetan yoga, 380
*Tinospora glabra*
  anticancer activity of, 47
  arabinogalactoses, 45
  biological activity
    antidiabetic, 46
    anti-inflammatory, 47
    antimicrobial, 47
    antioxident, 46
    antipyretic, 47
    antistress, 47
    cognition and memory
      enhancing, 47
    diuretic, 47
    hepatoprotective, 47
    immunomodulator, 47
  choline and tinosporic acid, 45
  cytotoxic effects against HeLa cells, 47
formulations
  fresh juice and paste, 45
  *Ghana* and *sattwa*, 45
  *ghrita* and *taila*, 45
  *kwath* and *arishta*, 45
  powder, 45
formulations of
  for leucopenia, 48
  samshamanivati, 48
  furano diterpenes
    columbin, 45
    cordiofolioside A and B, 45
    glucoside–tinocordiofoliside, 45
    phenylpropene disaccharides, 45
    sesquiterpene, 45
    tinosporaside, 45
    giloin and tinosporal, 45
  isolated alkaloids
    berberine, 45
    isocolumbine, 45
    jatrorhizine, 45
    palmatine, 45
    temletarine, 45
    tinosporin, 44–45
  medicinal plants in India, 44
  multi-ingredient formulations
    *Abhayadi kwath*, 46
    *Amrita-Bhallataka*, 45
    *Chandraprabhavati*, 46
    *Kaishor Guggulu*, 45
    *Rasnadi kwath*, 46
    *Samshamani vati*, 45
  phytochemistry of, 44
  safety studies
    antiangiogenic activity, 48
    aqueous extract effect, 48
    metastatic ovarian cancer treatment, 47
    teaklike extract, 47
    sterols and lactones, 45
    *Tinospora cordifolia* (Wild) Miers, 45
  phytoconstituents of, 46
Topoisomerase inhibitors, DNA poisons, 6
Topotecan, 6, 404, 424
  See also Topoisomerase inhibitors, DNA poisons
Toxicity, 407
  with black cohosh, 408
Trade-Related Aspects of Intellectual Property Rights (TRIPS), 537
Traditional and Alternative Medicine Act (1997), 539
Traditional Chinese medicine (TCM),
  25, 377, 385, 405, 678
  China Administration Bureau of, 27
criteria for diagnosis and
treatment, 27
formulations for, 27
holism theory, 26
theories
  blood and body fluid, 26
  essence and Qi, 26
  five elements, 26
  meridians and collaterals, 26
  viscera (Zang and Fu), 26
  Yin and Yang balance, 26
Traditional knowledge (TKDL), 538
  Trametes Versicolor, 412
  Transactivation function-1 (AF-1), 673
  Trastuzumab
  for HER-2.neu+ breast cancer, 7
  Trichostatin-A (TSA), 661
  Trimodality therapy, 13
  Tripterygium wilfordii, 412
Tumor
  benign and malignant types, 34
  staging
  and TNM classification, 5
Tumour necrosis factor-alpha
  (TNF-α), 42
Turmerone
  ar-turmerone, 58
  α and β, 58
Tween 80, 56

U
UDP-glucuronosyltransferase
  (UGT), 591
Ukonans A, B, C and D, 58
United States Patent and Trademark
  Office (USPTO), 530
Uracil-Tegafur (UFT) oral drug
  combination, 10–11
UV(B)-induced skin carcinoma, 42–43

V
Vaccinium myrtillus L.
  diabetic retinopathy for, 473
  inflammation of respiratory tract
  for, 473
  for treatment of chronic fatigue
  syndrome, 473
Vague pain, 159
Vascular endothelial growth factor
  (VEGF), 42
Velbe®, see Vinblastine
Velcade, see Bortezomib
Vepesid®, see Etoposide
Veregen™, 404
Vidarabine (Ara A) structure, 614
Vinblastine, 425
Vincristine, 6, 52, 425
Vinorelbine, 6
Viscera (Zang and Fu) theories, 26
  See also Traditional Chinese
  medicine (TCM)
Vitamin E, 377
Vorinostat for cutaneous lymphoma, 7
Vumon®, see Teniposide

W
Wang Bu Liu Xing Zi formulation,
  221–222
Warfarin, 411
Web references, safety and drug
  interactions
  of herbal formulations, 461
Wei Shu (BL 21) acupoints, 129–130
WHO Uppsala database of herbal
  ADRs, 460
Wisconsin ginseng, 377
Withaferin-A (WA), 40–41
  antitumor and radiosensitizing
  activities, 42
  inhibitor of TNF-α, 42
Withania somnifera
  antitumor and radiosensitizing
  activities, 42
  as anxiolytic, 43
  ayurvedic actions
    balya, 39
    rasayana, 39
    shothhara, 39
    vishaghana, 39
Withania somnifera L. (cont.)
  vrishya, 39
  ayurvedic properties of
    Guna–Laghu, 39
    Kashaya, 39
    Madhur, 39
    Rasa, 39
    Snigdha, 39
    Tikta, 39
    Veerya–Ushna, 39
    Vipaka, 39
  as cardioprotective, 43
  clinical and ayurvedic usage
    analgesic property, 43
    nutritive properties, 43
    as radiosensitizing agent, 44
    used in India, 44
    use in tumours and goiter, 43
  experimental studies, 40
  immunoprotection in cancer chemotherapy, 43
  immunostimulant properties, 43
  integrative oncology, role in, 39
  medicinal plant, 38
  MEDLINE and EBSCO databases, 39
  pharmacognosy of, 39
  phytochemistry of
    chemical constituents, 40
    phytoconstituents, 41
  powdered leaf extract, effect of
    osteogenic sarcoma and breast cancer, 42
  root powder/extracts
    chemopreventive and radioprotective effects, 42–43
    increase in lifespan, 43
    reduction in tumour metastases, 43
    in treatment of cancer, 39–40
    in tumourous lymphadenopathy, 40
  Withanolides and withanosides, 40
  Wu Ling San formulations, 150, 246

X
  X
    Xia Ku Cao formulation, 219
    Xingnaoqing, 176
    Xu Chang Qing formulation for pain, 199

Y
  Yang toxin, 156–157
  Yin and Yang balance theories, 26
    See also Traditional Chinese medicine (TCM)
  Yinchenhao decoction, 175
  Yinlingquan (SP9) acupoints, 256
  Yoga, 379
    effect of, 380
    meditation and, 378
    Tibetan, 380
    weekly, 380
  Yuan Hu formulation, 219
  Yu Jin formulation, 221

Z
  Z
    Zao Jiao Ci formulation, 221
    Zhang Shi Yi Tong, 187
    Zhen Wu Tang formulations, 150, 246
    Zhongji (CV3) acupoints, 256
    Zhong Wan (CV12), 129
    Zingiberene, 58
    Zi wu liu zhu principle, 178
      See also Acupuncture treatment
    Zolinza, see Vorinostat for cutaneous lymphoma
    Zu San Li (ST36) acupoints, 129–130, 150, 247, 256